|
EP2290073A3
(en)
|
2004-05-28 |
2011-08-31 |
Asuragen, Inc. |
Methods and compositions involving microRNA
|
|
EP2302055B1
(en)
|
2004-11-12 |
2014-08-27 |
Asuragen, Inc. |
Methods and compositions involving miRNA and miRNA inhibitor molecules
|
|
EP1877557A2
(en)
|
2005-04-04 |
2008-01-16 |
The Board of Regents of The University of Texas System |
Micro-rna's that regulate muscle cells
|
|
US20090131348A1
(en)
*
|
2006-09-19 |
2009-05-21 |
Emmanuel Labourier |
Micrornas differentially expressed in pancreatic diseases and uses thereof
|
|
AU2008248319B2
(en)
*
|
2007-04-30 |
2013-09-05 |
The Ohio State University Research Foundation |
Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
|
|
WO2009036332A1
(en)
|
2007-09-14 |
2009-03-19 |
Asuragen, Inc. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
|
KR20100099158A
(ko)
|
2007-11-09 |
2010-09-10 |
보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 |
심근세포 생존과 심장 회복을 제어하는 ＭＩＲ-15 집단의 마이크로ＲＮＡｓ
|
|
WO2009070805A2
(en)
|
2007-12-01 |
2009-06-04 |
Asuragen, Inc. |
Mir-124 regulated genes and pathways as targets for therapeutic intervention
|
|
EP2265291B1
(en)
|
2008-03-17 |
2016-10-19 |
The Board of Regents of The University of Texas System |
Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
|
|
WO2009137807A2
(en)
|
2008-05-08 |
2009-11-12 |
Asuragen, Inc. |
Compositions and methods related to mirna modulation of neovascularization or angiogenesis
|
|
US7888035B2
(en)
|
2008-10-30 |
2011-02-15 |
Caris Mpi, Inc. |
Methods for assessing RNA patterns
|
|
WO2010054386A2
(en)
*
|
2008-11-10 |
2010-05-14 |
Battelle Memorial Institute |
Methods, compositions, and devices utilizing microrna to determine physiological conditions
|
|
WO2010056337A2
(en)
|
2008-11-12 |
2010-05-20 |
Caris Mpi, Inc. |
Methods and systems of using exosomes for determining phenotypes
|
|
US9074206B2
(en)
|
2008-11-13 |
2015-07-07 |
Fudan University |
Compositions and methods for micro-RNA expression profiling of colorectal cancer
|
|
EP2542696B1
(en)
|
2010-03-01 |
2016-09-28 |
Caris Life Sciences Switzerland Holdings GmbH |
Biomarkers for theranostics
|
|
JP2013526852A
(ja)
|
2010-04-06 |
2013-06-27 |
カリス ライフ サイエンシズ ルクセンブルク ホールディングス |
疾患に対する循環バイオマーカー
|
|
CN103080334B
(zh)
*
|
2010-06-04 |
2016-05-04 |
复旦大学 |
用于诊断早期结直肠癌及高级腺瘤的微rna生物标记及方法
|
|
EP2591106A1
(en)
|
2010-07-06 |
2013-05-15 |
InteRNA Technologies B.V. |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
|
CA2812650C
(en)
*
|
2010-09-27 |
2019-11-05 |
Sabanci Universitesi |
Use of mirnas for the diagnosis, prophylaxis, treatment and follow-up of diseases involving macroautophagy abnormalities
|
|
EP2474617A1
(en)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
|
WO2013040251A2
(en)
|
2011-09-13 |
2013-03-21 |
Asurgen, Inc. |
Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
|
|
CA2859021A1
(en)
|
2011-12-19 |
2013-06-27 |
Valley Health System |
Methods and kits for detecting subjects at risk of having cancer
|
|
WO2013101783A2
(en)
|
2011-12-30 |
2013-07-04 |
Bio-Rad Laboratories, Inc. |
Methods and compositions for performing nucleic acid amplification reactions
|
|
US9334498B2
(en)
|
2012-05-10 |
2016-05-10 |
Uab Research Foundation |
Methods and compositions for modulating MIR-204 activity
|
|
US9163235B2
(en)
|
2012-06-21 |
2015-10-20 |
MiRagen Therapeutics, Inc. |
Inhibitors of the miR-15 family of micro-RNAs
|
|
WO2014043159A1
(en)
*
|
2012-09-11 |
2014-03-20 |
New York University |
Sera based mirnas as non-invasive biomarkers in melanoma
|
|
WO2014093924A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
PL2922554T3
(pl)
|
2012-11-26 |
2022-06-20 |
Modernatx, Inc. |
Na zmodyfikowany na końcach
|
|
PL3360964T3
(pl)
*
|
2012-12-06 |
2020-03-31 |
Sigma-Aldrich Co. Llc |
Modyfikacja i regulacja genomu oparta na crispr
|
|
AU2013374345A1
(en)
|
2013-01-17 |
2015-08-06 |
Moderna Therapeutics, Inc. |
Signal-sensor polynucleotides for the alteration of cellular phenotypes
|
|
KR101501562B1
(ko)
*
|
2013-04-05 |
2015-03-11 |
연세대학교 산학협력단 |
췌장암 진단 마커를 검출하는 방법
|
|
US20150018230A1
(en)
*
|
2013-06-11 |
2015-01-15 |
Indiana University Research And Technology Corp. |
PLASMA miRNA SIGNATURE FOR THE ACCURATE DIAGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA
|
|
JP6611411B2
(ja)
*
|
2013-12-05 |
2019-11-27 |
東レ株式会社 |
膵臓がんの検出キット及び検出方法
|
|
CA2939343A1
(en)
|
2014-02-18 |
2015-08-27 |
Baylor Research Institute |
Mir-320e and colorectal cancer
|
|
EP3115467B1
(en)
|
2014-03-04 |
2019-01-02 |
Hiroshima University |
Method for assisting detection of pancreatic cancer
|
|
EP4438743A3
(en)
*
|
2014-05-30 |
2024-12-25 |
Toray Industries, Inc. |
Pancreatic cancer detection kit or device, and detection method
|
|
US9623040B2
(en)
|
2014-07-14 |
2017-04-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Immunomodulation by controlling expression levels of microRNAs in dendritic cells
|
|
WO2016077125A1
(en)
|
2014-11-10 |
2016-05-19 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules containing reduced uracil content and uses thereof
|
|
JP2016123340A
(ja)
*
|
2014-12-26 |
2016-07-11 |
株式会社エバンス |
膵癌治療感受性の診断方法及び膵癌治療感受性の増強剤
|
|
EP3405579A1
(en)
|
2016-01-22 |
2018-11-28 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
|
CA3018048A1
(en)
|
2016-03-31 |
2017-10-05 |
Toray Industries, Inc. |
Kit or device for detecting early stage pancreatic cancer or pancreatic cancer precursor lesions and detection method therefor
|
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
SI3458083T1
(sl)
|
2016-05-18 |
2023-03-31 |
Modernatx, Inc. |
Polinukleotidi, ki kodirajo interlevkin-12 (IL12) in njihova uporaba
|
|
WO2017218704A1
(en)
|
2016-06-14 |
2017-12-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
CN109661228A
(zh)
*
|
2016-06-20 |
2019-04-19 |
库拉肿瘤学公司 |
用erk抑制剂治疗鳞状细胞癌
|
|
EP4484443A3
(en)
|
2016-06-29 |
2025-03-26 |
CRISPR Therapeutics AG |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
|
US11174469B2
(en)
|
2016-06-29 |
2021-11-16 |
Crispr Therapeutics Ag |
Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
|
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
|
CN109843914B
(zh)
|
2016-07-06 |
2024-03-15 |
沃泰克斯药物股份有限公司 |
用于治疗疼痛相关病症的材料和方法
|
|
JP7305534B2
(ja)
|
2016-07-06 |
2023-07-10 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
疼痛関連障害を処置するための物質及び方法
|
|
CN110402145A
(zh)
|
2016-10-26 |
2019-11-01 |
莫得纳特斯公司 |
用于增强免疫应答的信使核糖核酸及其使用方法
|
|
US11584932B2
(en)
|
2016-11-01 |
2023-02-21 |
The Research Foundation For The State University Of New York |
5-halouracil-modified microRNAs and their use in the treatment of cancer
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
BR112019015797A2
(pt)
|
2017-02-01 |
2020-03-17 |
Modernatx, Inc. |
Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
|
|
EP3585898A1
(en)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
|
|
EP3585900B1
(en)
|
2017-02-22 |
2022-12-21 |
CRISPR Therapeutics AG |
Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
|
|
EP3585895A1
(en)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Compositions and methods for gene editing
|
|
WO2018154459A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
|
|
EP3585807A1
(en)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
|
US20200131498A1
(en)
|
2017-06-14 |
2020-04-30 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
|
US10636512B2
(en)
|
2017-07-14 |
2020-04-28 |
Cofactor Genomics, Inc. |
Immuno-oncology applications using next generation sequencing
|
|
EP3675817A1
(en)
|
2017-08-31 |
2020-07-08 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
CA3082450A1
(en)
|
2017-11-21 |
2019-05-31 |
Crispr Therapeutics Ag |
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
|
|
US20230167504A1
(en)
*
|
2017-12-13 |
2023-06-01 |
Hiroshima University |
Method for aiding detection of pancreatic cancer
|
|
AU2018393050A1
(en)
|
2017-12-21 |
2020-06-18 |
Bayer Healthcare Llc |
Materials and methods for treatment of Usher Syndrome Type 2A
|
|
US20190314291A1
(en)
|
2018-01-30 |
2019-10-17 |
Modernatx, Inc. |
Compositions and methods for delivery of agents to immune cells
|
|
EP3773745A1
(en)
|
2018-04-11 |
2021-02-17 |
ModernaTX, Inc. |
Messenger rna comprising functional rna elements
|
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
US20210386788A1
(en)
|
2018-10-24 |
2021-12-16 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
CN118697900A
(zh)
|
2019-01-31 |
2024-09-27 |
摩登纳特斯有限公司 |
制备脂质纳米颗粒的方法
|
|
MX2021010840A
(es)
|
2019-03-08 |
2022-01-19 |
Obsidian Therapeutics Inc |
Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable.
|
|
WO2020218489A1
(ja)
*
|
2019-04-26 |
2020-10-29 |
国立大学法人大阪大学 |
トンネル電流を使用したマイクロｒｎａ解析
|
|
US20220387628A1
(en)
|
2019-06-24 |
2022-12-08 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements and uses thereof
|
|
EP3987027A1
(en)
|
2019-06-24 |
2022-04-27 |
ModernaTX, Inc. |
Endonuclease-resistant messenger rna and uses thereof
|
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
CA3169669A1
(en)
|
2020-01-31 |
2021-08-05 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
|
US11965162B2
(en)
*
|
2020-04-16 |
2024-04-23 |
The Johns Hopkins University |
MicroRNA and inhibitors thereof and methods of treatment
|
|
WO2021262919A2
(en)
|
2020-06-26 |
2021-12-30 |
The Research Foundation For The State University Of New York |
5-halouracil-modified micrornas and their use in the treatment of cancer
|
|
US20230272481A1
(en)
*
|
2020-07-16 |
2023-08-31 |
Kurume University |
Use of microrna as pancreatic cancer biomarker
|
|
EP4185274A1
(en)
|
2020-07-24 |
2023-05-31 |
Strand Therapeutics Inc. |
Lipidnanoparticle comprising modified nucleotides
|
|
EP4192432A1
(en)
|
2020-08-06 |
2023-06-14 |
ModernaTX, Inc. |
Methods of preparing lipid nanoparticles
|
|
AR124599A1
(es)
|
2021-01-08 |
2023-04-12 |
Strand Therapeutics Inc |
Constructos de expresión y usos de estos
|
|
EP4334446A1
(en)
|
2021-05-03 |
2024-03-13 |
CureVac SE |
Improved nucleic acid sequence for cell type specific expression
|
|
WO2023166425A1
(en)
|
2022-03-01 |
2023-09-07 |
Crispr Therapeutics Ag |
Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
|
|
CN119317430A
(zh)
|
2022-04-26 |
2025-01-14 |
斯特兰德生物科技公司 |
包含委内瑞拉马脑炎(vee)复制子的脂质纳米颗粒及其用途
|
|
WO2024026482A1
(en)
|
2022-07-29 |
2024-02-01 |
Modernatx, Inc. |
Lipid nanoparticle compositions comprising surface lipid derivatives and related uses
|
|
US20250375389A1
(en)
|
2022-07-29 |
2025-12-11 |
Modernatx, Inc. |
Lipid nanoparticle compositions comprising phospholipid derivatives and related uses
|
|
WO2024026475A1
(en)
|
2022-07-29 |
2024-02-01 |
Modernatx, Inc. |
Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses
|
|
KR20260006623A
(ko)
|
2023-04-28 |
2026-01-13 |
센젠 센신 바이오테크놀로지 컴퍼니 리미티드 |
변형된 전달 담체 및 이의 용도
|
|
WO2024259373A1
(en)
|
2023-06-14 |
2024-12-19 |
Modernatx, Inc. |
Compounds and compositions for delivery of therapeutic agents
|
|
WO2025160381A1
(en)
|
2024-01-26 |
2025-07-31 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
|
WO2025166202A1
(en)
|
2024-01-31 |
2025-08-07 |
Modernatx, Inc. |
Lipid nanoparticle compositions comprising sialic acid derivatives and the uses thereof
|
|
ES3048857A1
(es)
*
|
2024-06-10 |
2025-12-11 |
Fundacion Para La Investig E Innovacion Biosanitaria Del Principado De Asturias Finba |
FIRMA DE miRNA UTILES EN LA DISCRIMINACION DE TUMORES
|
|
CN119391860B
(zh)
*
|
2024-12-25 |
2025-03-21 |
慧算基因科技(上海)有限公司 |
一种用于胰腺癌术后mrd检测及动态监测的引物探针组合物、试剂盒及应用
|